Literature DB >> 24280967

Polypoidal choroidal vasculopathy: clinical features and genetic predisposition.

Shigeru Honda1, Wataru Matsumiya, Akira Negi.   

Abstract

Polypoidal choroidal vasculopathy (PCV) is currently recognized as a phenotype of age-related macular degeneration (AMD). PCV is believed to be a type of choroidal neovascularization, although some cases of PCV show a distinct vascular abnormality of the choroidal vessels. PCV often shows several unique clinical manifestations which are apparently different from typical neovascular AMD (tAMD). In addition, the natural course and response to treatment are often different between tAMD and PCV. Moreover, recent genetic studies suggested a possible difference in the genetic susceptibility to disease between tAMD and PCV, as well as the existence of heterogeneity among PCV cases. In viewing the accumulation of knowledge about PCV, we have summarized the recent literature regarding PCV in this review article to improve the understanding of this clinical entity including possible susceptibility genes. We will also discuss the optimal treatment strategies for PCV in accordance with the results of recent clinical and genetic studies.
© 2013 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2013        PMID: 24280967     DOI: 10.1159/000355488

Source DB:  PubMed          Journal:  Ophthalmologica        ISSN: 0030-3755            Impact factor:   3.250


  31 in total

Review 1.  Idiopathic polypoidal choroidal vasculopathy: a review of literature with clinical update on current management practices.

Authors:  Yamini Sahu; Niharika Chaudhary; Mukesh Joshi; Aastha Gandhi
Journal:  Int Ophthalmol       Date:  2020-10-20       Impact factor: 2.031

2.  A missense variant in FGD6 confers increased risk of polypoidal choroidal vasculopathy.

Authors:  Lulin Huang; Houbin Zhang; Ching-Yu Cheng; Feng Wen; Pancy O S Tam; Peiquan Zhao; Haoyu Chen; Zheng Li; Lijia Chen; Zhengfu Tai; Kenji Yamashiro; Shaoping Deng; Xianjun Zhu; Weiqi Chen; Li Cai; Fang Lu; Yuanfeng Li; Chui-Ming G Cheung; Yi Shi; Masahiro Miyake; Yin Lin; Bo Gong; Xiaoqi Liu; Kar-Seng Sim; Jiyun Yang; Keisuke Mori; Xiongzhe Zhang; Peter D Cackett; Motokazu Tsujikawa; Kohji Nishida; Fang Hao; Shi Ma; He Lin; Jing Cheng; Ping Fei; Timothy Y Y Lai; Sibo Tang; Augustinus Laude; Satoshi Inoue; Ian Y Yeo; Yoichi Sakurada; Yu Zhou; Hiroyuki Iijima; Shigeru Honda; Chuntao Lei; Lin Zhang; Hong Zheng; Dan Jiang; Xiong Zhu; Tien-Ying Wong; Chiea-Chuen Khor; Chi-Pui Pang; Nagahisa Yoshimura; Zhenglin Yang
Journal:  Nat Genet       Date:  2016-04-18       Impact factor: 38.330

3.  Severity of age-related macular degeneration at first presentation in Bhutan: a 3-year national study.

Authors:  Bhim B Rai; Michael G Morley; Paul S Bernstein; Ted Maddess
Journal:  BMC Ophthalmol       Date:  2022-07-09       Impact factor: 2.086

4.  One-year real-world outcomes of ranibizumab 0.5 mg treatment in Taiwanese patients with polypoidal choroidal vasculopathy: a subgroup analysis of the REAL study.

Authors:  San-Ni Chen; Cheng-Kuo Cheng; Ling Yeung; Jiann-Torng Chen; Wei-Chun Chan; Jorn-Hon Liu; Shwu-Jiuan Sheu; Wen-Chuan Wu; Chi-Chun Lai
Journal:  Int J Ophthalmol       Date:  2018-11-18       Impact factor: 1.779

5.  Efficacy and Safety of Ranibizumab With or Without Verteporfin Photodynamic Therapy for Polypoidal Choroidal Vasculopathy: A Randomized Clinical Trial.

Authors:  Adrian Koh; Timothy Y Y Lai; Kanji Takahashi; Tien Y Wong; Lee-Jen Chen; Paisan Ruamviboonsuk; Colin S Tan; Chrystel Feller; Philippe Margaron; Tock H Lim; Won Ki Lee
Journal:  JAMA Ophthalmol       Date:  2017-11-01       Impact factor: 7.389

6.  The association of elastin gene variants with two angiographic subtypes of polypoidal choroidal vasculopathy.

Authors:  Suiho Yanagisawa; Yoichi Sakurada; Akiko Miki; Wataru Matsumiya; Issei Imoto; Shigeru Honda
Journal:  PLoS One       Date:  2015-03-16       Impact factor: 3.240

7.  Treatment Outcomes in Patients with Polypoidal Choroidal Vasculopathy.

Authors:  Işıl Sayman Muslubaş; Mümin Hocaoğlu; Serra Arf; Hakan Özdemir; Murat Karaçorlu
Journal:  Turk J Ophthalmol       Date:  2016-01-05

8.  C3a Increases VEGF and Decreases PEDF mRNA Levels in Human Retinal Pigment Epithelial Cells.

Authors:  Qin Long; Xiaoguang Cao; Ailing Bian; Ying Li
Journal:  Biomed Res Int       Date:  2016-09-22       Impact factor: 3.411

9.  Practicability confirmation by meta-analysis of intravitreal ranibizumab compared to photodynamic therapy to treat polypoidal choroidal vasculopathy.

Authors:  Ling Liu; Jie Ma; Ping Duan; Yong Liu; Zheng Qin Yin
Journal:  Mol Vis       Date:  2015-10-03       Impact factor: 2.367

10.  EVEREST study report 3: diagnostic challenges of polypoidal choroidal vasculopathy. Lessons learnt from screening failures in the EVEREST study.

Authors:  Colin S Tan; Wei Kiong Ngo; Louis W Lim; Nikolle W Tan; Tock H Lim
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-05-03       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.